

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10536552
Filing Date	2006-01-26
First Named Inventor	Wallukat et al.
Art Unit	1644
Examiner Name	David A. Saunders
Attorney Docket Number	3035-111

U.S.PATENTS**Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
1	4468470			1984-04-28	Stichting Centraal Laboratorium van de Bloedtransf	
2	0994970		B1	2000-02-07	Fresenius Medical Care Affina GmbH	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add**U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add**FOREIGN PATENT DOCUMENTS****Remove**

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
1	01/21660 OF RECORD		WO	A1	2001-03-29	WALLUKAT GERD et al.	ISR which refers to peptide 2 of claim 3	<input type="checkbox"/>
2	100 20 442		DE	A1	1999-12-09	AFFINA IMMUNTECHNIK GMBH	ISR NO ENG ABSTR	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>			Application Number		10536552			
			Filing Date		2006-01-26			
			First Named Inventor		Wallukat et al.			
			Art Unit			1644		
			Examiner Name			David A. Saunders		
			Attorney Docket Number			3035-111		

	3	2004/067549	WO	A2	2004-08-12	MAX DELBRUECK CENTRUM et al.	ISR ABSTR ONLY IN ENG	<input type="checkbox"/>
	4	02/16431	WO	A2	2002-02-28	Max Delbrück Centrum	ABSTRACT	<input type="checkbox"/>
	5	101 23 929	DE	A1	2002-11-21	Celltrend GmbH	ABSTRACT	<input type="checkbox"/>
	6	00/39154	WO	A2	2000-07-06	Max Delbrück Centrum	ABSTRACT	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	<input type="checkbox"/> T ⁵
	1	*WALLUKAT GERM ET AL: "Spontaneously beating neonatal rat heart myocyte culture: A model to characterize angiotensin II AT1 receptor autoantibodies in patients with preeclampsia." in: IN VITRO CELLULAR AND DEVELOPMENTAL BIOLOGY ANIMAL, vol. 38, no. 7, 2002, pp.: 376-377	<input type="checkbox"/>
	2	* WALLUKAT G ET AL: "Anti-Beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy. Mapping of epitopes in the first and second extracellular loops" in: JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 27, 1995, pp.: 397-406	<input type="checkbox"/>
	3	* STAUDT ALEXANDER ET AL: "Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy." in: CIRCULATION, vol. 106, no. 19, 2002, pp.: 2448-2453	<input type="checkbox"/>
		REFS 2 & 3 OF RECORD	
	4	* WALLUKAT GERM ET AL: "Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy." in: NEW ENGLAND JOURNAL OF MEDICINE, vol. 347, no. 22, 2002-11-28, p.: 1806	<input type="checkbox"/>
	5	* WALLUKAT GERM ET AL: "Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy" in: HERZ, vol. 25, no. 3, 2000, pp.: 261-266	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10536552
	Filing Date	2006-01-26
	First Named Inventor	Wallukat et al.
	Art Unit	1644
	Examiner Name	David A. Saunders
	Attorney Docket Number	3035-111

6	* FU MICHAEL L X ET AL: "A synthetic Peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits" CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 78, no. 2, 1996, pp.: 203-207	<input type="checkbox"/>
7	* MARINO MARIA ET AL: "Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide" . NATURE BIOTECHNOLOGY, vol. 18, no. 7, 2000-07, pp.: 735-739	<input type="checkbox"/>
8	* BOROS PETER ET AL: "Specificity and class distribution of Fc-gamma-R-specific autoantibodies in patients with autoimmune disease" in: JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 152, 1994, pp.: 302-306	<input type="checkbox"/>
9	* MACFARLANE S R ET AL: "Proteinase-activated receptors" in: PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD., US, vol. 53, no. 2, 2001-06, pp.: 245-282	<input type="checkbox"/>
10	* BELCH J J F: "Raynaud's phenomenon" in: CURRENT OPINION IN RHEUMATOLOGY, vol. 3, no. 6, 1991, pp.: 960-966	<input type="checkbox"/>
11	DRAGUN D ET AL: "Patients With Steroid Refractory Acute Vascular Rejection Develop Agonistic Antibodies Targeting Angiotensin II Type 1 Receptor" in: Transplantation Proceedings, vol.35, no.6, 2003-09-06, pp.: 2104-2105	<input type="checkbox"/>
12	DRAGUN D ET AL: "Steroid-Resistant Vascular Rejection Due to Agonistic ATI-Receptor Antibodies Causing Expression of TF, MCP-1, and RANTES" in: Journal of the American Society of Nephrology, vol.12, 2001-09, p.: 930A	<input type="checkbox"/>
13	LUTHER ET AL: "Alpha1-adrenergic receptor antibodies in patients with primary hypertension" in: Hypertension, vol. 29, no. 2, 1997, pp.: 678-682	<input type="checkbox"/>
14	LIAO ET AL: "Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension" in: Official Journal of the Japanese Society of Hypertension, vol. 25, no. 4, July 2002, pp.: 641-646	<input type="checkbox"/>
15	FU ET AL: "Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension" in: Lancet, vol. 344, no. 8938, 1994, p.: 1660	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10536552
	Filing Date	2006-01-26
	First Named Inventor	Wallukat et al.
	Art Unit	1644
	Examiner Name	David A. Saunders
	Attorney Docket Number	3035-111

EXAMINER SIGNATURE

Examiner Signature	/David Saunders/	Date Considered	04/10/2009
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.